Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

155.46
+2.801.83%
Post-market: 155.460.00000.00%19:47 EDT
Volume:987.64K
Turnover:153.31M
Market Cap:7.65B
PE:-53.38
High:158.76
Open:155.62
Low:153.05
Close:152.66
52wk High:228.88
52wk Low:91.86
Shares:49.22M
Float Shares:48.62M
Volume Ratio:1.00
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9122
EPS(LYR):-2.9122
ROE:-4.23%
ROA:4.24%
PB:2.42
PE(LYR):-53.38

Loading ...

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 14

Press Release: Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Dow Jones
·
Mar 12

Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals

Benzinga_recent_news
·
Mar 12

Seikagaku Resubmits U.S. Application for Disc Herniation Drug After Addressing FDA Concerns

MT Newswires Live
·
Mar 10

Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Mar 10

Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193

MT Newswires Live
·
Mar 09

Charles River Laboratories International Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 07

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 05

Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working?

Simply Wall St.
·
Mar 04

Charles River Laboratories International Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Mar 04

Charles River Laboratories to Present at TD Cowen and Barclays Investor Conferences

Reuters
·
Mar 02

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 28

Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Feb 26

Barclays Remains a Buy on Charles River Labs (CRL)

TIPRANKS
·
Feb 26

Charles River Labs Is Maintained at Neutral by UBS

Dow Jones
·
Feb 26

UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating

MT Newswires Live
·
Feb 25

Charles River raises annual profit view as it sells underperforming assets

Reuters
·
Feb 25

Iqvia to acquire certain discovery services assets from Charles River

TIPRANKS
·
Feb 25

GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30

MT Newswires Live
·
Feb 25

Charles River signs deals to sell European Discovery Services assets and CDMO and Cell Solutions businesses

Reuters
·
Feb 25